176 related articles for article (PubMed ID: 16391828)
21. Microarray analysis reveals potential target genes of NF-kappaB2/p52 in LNCaP prostate cancer cells.
Nadiminty N; Dutt S; Tepper C; Gao AC
Prostate; 2010 Feb; 70(3):276-87. PubMed ID: 19827050
[TBL] [Abstract][Full Text] [Related]
22. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
[TBL] [Abstract][Full Text] [Related]
23. GREB1 is a novel androgen-regulated gene required for prostate cancer growth.
Rae JM; Johnson MD; Cordero KE; Scheys JO; Larios JM; Gottardis MM; Pienta KJ; Lippman ME
Prostate; 2006 Jun; 66(8):886-94. PubMed ID: 16496412
[TBL] [Abstract][Full Text] [Related]
24. Bone morphogenetic protein signaling in prostate cancer cell lines.
Brubaker KD; Corey E; Brown LG; Vessella RL
J Cell Biochem; 2004 Jan; 91(1):151-60. PubMed ID: 14689587
[TBL] [Abstract][Full Text] [Related]
25. Expression profiling of androgen-dependent and -independent LNCaP cells: EGF versus androgen signalling.
Oosterhoff JK; Grootegoed JA; Blok LJ
Endocr Relat Cancer; 2005 Mar; 12(1):135-48. PubMed ID: 15788645
[TBL] [Abstract][Full Text] [Related]
26. Doxazosin induces apoptosis in LNCaP prostate cancer cell line through DNA binding and DNA-dependent protein kinase down-regulation.
Arencibia JM; Del Rio M; Bonnin A; Lopes R; Lemoine NR; López-Barahona M
Int J Oncol; 2005 Dec; 27(6):1617-23. PubMed ID: 16273218
[TBL] [Abstract][Full Text] [Related]
27. Androgen dependent regulation of protein kinase A subunits in prostate cancer cells.
Kvissel AK; Ramberg H; Eide T; Svindland A; Skålhegg BS; Taskén KA
Cell Signal; 2007 Feb; 19(2):401-9. PubMed ID: 16949795
[TBL] [Abstract][Full Text] [Related]
28. The synthetic estrogen diethylstilbestrol (DES) inhibits the telomerase activity and gene expression of prostate cancer cells.
Geier R; Adler S; Rashid G; Klein A
Prostate; 2010 Sep; 70(12):1307-12. PubMed ID: 20623632
[TBL] [Abstract][Full Text] [Related]
29. Up-regulated expression of the MAT-8 gene in prostate cancer and its siRNA-mediated inhibition of expression induces a decrease in proliferation of human prostate carcinoma cells.
Grzmil M; Voigt S; Thelen P; Hemmerlein B; Helmke K; Burfeind P
Int J Oncol; 2004 Jan; 24(1):97-105. PubMed ID: 14654946
[TBL] [Abstract][Full Text] [Related]
30. HGF/SF up-regulates the expression of bone morphogenetic protein 7 in prostate cancer cells.
Ye L; Lewis-Russell JM; Sanders AJ; Kynaston H; Jiang WG
Urol Oncol; 2008; 26(2):190-7. PubMed ID: 18312940
[TBL] [Abstract][Full Text] [Related]
31. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA
Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446
[TBL] [Abstract][Full Text] [Related]
32. YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity.
Giménez-Bonafé P; Fedoruk MN; Whitmore TG; Akbari M; Ralph JL; Ettinger S; Gleave ME; Nelson CC
Prostate; 2004 May; 59(3):337-49. PubMed ID: 15042610
[TBL] [Abstract][Full Text] [Related]
33. BMP2 and BMP6 control p57(Kip2) expression and cell growth arrest/terminal differentiation in normal primary human epidermal keratinocytes.
Gosselet FP; Magnaldo T; Culerrier RM; Sarasin A; Ehrhart JC
Cell Signal; 2007 Apr; 19(4):731-9. PubMed ID: 17112701
[TBL] [Abstract][Full Text] [Related]
34. The mature bone morphogenetic protein-2 is aberrantly expressed in non-small cell lung carcinomas and stimulates tumor growth of A549 cells.
Langenfeld EM; Calvano SE; Abou-Nukta F; Lowry SF; Amenta P; Langenfeld J
Carcinogenesis; 2003 Sep; 24(9):1445-54. PubMed ID: 12819188
[TBL] [Abstract][Full Text] [Related]
35. Bone morphogenetic protein-2 suppresses invasiveness of TSU-Pr1 cells with the inhibition of MMP-9 secretion.
Kumagai T; Shimizu T; Takeda K
Anticancer Res; 2006; 26(1A):293-8. PubMed ID: 16475709
[TBL] [Abstract][Full Text] [Related]
36. Increased expression of bone morphogenetic protein-7 in bone metastatic prostate cancer.
Masuda H; Fukabori Y; Nakano K; Takezawa Y; CSuzuki T; Yamanaka H
Prostate; 2003 Mar; 54(4):268-74. PubMed ID: 12539225
[TBL] [Abstract][Full Text] [Related]
37. IFI16 in human prostate cancer.
Alimirah F; Chen J; Davis FJ; Choubey D
Mol Cancer Res; 2007 Mar; 5(3):251-9. PubMed ID: 17339605
[TBL] [Abstract][Full Text] [Related]
38. Down-regulation of macrophage inhibitory cytokine-1/prostate derived factor in benign prostatic hyperplasia.
Kakehi Y; Segawa T; Wu XX; Kulkarni P; Dhir R; Getzenberg RH
Prostate; 2004 Jun; 59(4):351-6. PubMed ID: 15065082
[TBL] [Abstract][Full Text] [Related]
39. Partitioning of 5alpha-dihydrotestosterone and 5alpha-androstane-3alpha, 17beta-diol activated pathways for stimulating human prostate cancer LNCaP cell proliferation.
Nunlist EH; Dozmorov I; Tang Y; Cowan R; Centola M; Lin HK
J Steroid Biochem Mol Biol; 2004 Jul; 91(3):157-70. PubMed ID: 15276623
[TBL] [Abstract][Full Text] [Related]
40. A cross-talk between the androgen receptor and the epidermal growth factor receptor leads to p38MAPK-dependent activation of mTOR and cyclinD1 expression in prostate and lung cancer cells.
Recchia AG; Musti AM; Lanzino M; Panno ML; Turano E; Zumpano R; Belfiore A; Andò S; Maggiolini M
Int J Biochem Cell Biol; 2009 Mar; 41(3):603-14. PubMed ID: 18692155
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
